SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

NCT05570825 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8

Interventions

PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: CXCR1/2 Inhibitor SX-682
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Pembrolizumab
PROCEDURE: Positron Emission Tomography

Sponsor

University of Washington

Collaborators

[object Object]
[object Object]